

# MEP50 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP6771b

## Specification

## MEP50 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

<u>Q9BQA1</u>

## MEP50 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 79084

**Other Names** 

Methylosome protein 50, MEP-50, Androgen receptor cofactor p44, WD repeat-containing protein 77, p44/Mep50, WDR77, MEP50, WD45

### Target/Specificity

The synthetic peptide sequence used to generate the antibody <a

href=/products/AP6771b>AP6771b</a> was selected from the C-term region of human MEP50. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### **Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## MEP50 Antibody (C-term) Blocking Peptide - Protein Information

Name WDR77 (<u>HGNC:29652</u>)

#### Function

Non-catalytic component of the methylosome complex, composed of PRMT5, WDR77 and CLNS1A, which modifies specific arginines to dimethylarginines in several spliceosomal Sm proteins and histones (PubMed:<a href="http://www.uniprot.org/citations/11756452" target="\_blank">11756452</a>). This modification targets Sm proteins to the survival of motor

neurons (SMN) complex for assembly into small nuclear ribonucleoprotein core particles. Might play a role in transcription regulation. The methylosome complex also methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage (PubMed:<a href="http://www.uniprot.org/citations/23071334" target="\_blank">23071334</a>).

**Cellular Location** 



Nucleus. Cytoplasm. Note=Nuclear in Leydig cells and cytoplasmic in germ cells during fetal testicular development. In adult testis, predominantly nuclear. Subcellular location varies from nuclear to cytoplasmic in various tumors (PubMed:17437848).

### **Tissue Location**

Highly expressed in heart, skeletal muscle, spleen, testis, uterus, prostate and thymus. In testis, expressed in germ cells and Leydig cells, but not in peritubular myocytes, nor in Sertoli cells. Expressed in prostate cancers, in seminomas and in Leydig cell tumors.

## MEP50 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### <u>Blocking Peptides</u>

## MEP50 Antibody (C-term) Blocking Peptide - Images

## MEP50 Antibody (C-term) Blocking Peptide - Background

WDR77 is a component of the 20S PRMT5 (MIM 604045)-containing ethyltransferase complex, which modifies specific arginines to dimethylarginines in several spliceosomal Sm proteins (see MIM 601061). This modification targets Sm proteins to the survival of motor neurons (SMN) complex (see MIM 600354) for assembly into small nuclear ribonucleoprotein core particles.

## MEP50 Antibody (C-term) Blocking Peptide - References

Peng,Y., et.al., Proc. Natl. Acad. Sci. U.S.A. 105 (13), 5236-5241 (2008)